文献速递白血病造血干细胞移植与细胞治疗

一种新型嵌合抗原受体将T细胞特异性重定向至CD26阳性癌细胞

A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells.
PubMed 文献 · Leukemia · 2020-04-21

研究构建了靶向CD26的CAR T细胞,经慢病毒转导、流式细胞术和RNA测序验证。CD26 CAR T细胞对CD26阳性T细胞淋巴瘤细胞系Karpas 299、过表达CD26的K562细胞及原代CML白血病干细胞有细胞毒性,在小鼠模型中限制肿瘤进展,但对活化淋巴细胞有脱靶细胞毒性。结论认为CD26作为CAR T细胞抗原靶向CD26阳性肿瘤细胞具有可行性。

要点

  • CD26 CAR T细胞初始扩增因短暂自相残杀而延迟,后续扩增加速。
  • 对CD26阳性Karpas 299、过表达CD26的K562及原代CML白血病干细胞有细胞毒性。
  • 小鼠模型中限制肿瘤进展,但对活化淋巴细胞有脱靶细胞毒性。

核心结论

  • 结果确立了使用CD26作为CAR T细胞抗原靶向CD26阳性肿瘤细胞的可行性。

研究设计与样本

  • 利用慢病毒转导方法构建CD26 CAR T细胞,并通过流式细胞术分析和RNA测序进行验证。
  • 在CD26阳性T细胞淋巴瘤细胞系Karpas 299、过表达CD26的K562细胞和原代CML白血病干细胞中评估细胞毒性和效应功能,并在小鼠模型中评估肿瘤进展。

主要发现

  • CD26 CAR转导的T细胞初始扩增因短暂自相残杀而延迟,但后续扩增加速。
  • CD26 CAR T细胞对CD26阳性T细胞淋巴瘤细胞系Karpas 299、过表达CD26的K562细胞和原代CML白血病干细胞表现出细胞毒性。
  • 在共培养实验中激活多种效应功能,并在小鼠模型中限制肿瘤进展。
  • 对活化淋巴细胞存在一定的脱靶细胞毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 对活化淋巴细胞存在一定的脱靶细胞毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell immunotherapy is rapidly emerging as a promising novel treatment for malignancies. To broaden the success of CAR T-cell treatment for chronic myeloid leukaemia (CML), we attempted to construct a CD26 CAR T-cell product to target tyrosine kinase inhibitor-insensitive leukaemia stem cells (LSCs), which have been a challenge to cure for several decades and can be discriminated from healthy stem cells by the robust biomarker CD26. Of additional interest is that CD26 has also been reported to be a multi-purpose therapeutic target for other malignancies. Here, we constructed CD26 CAR T cells utilizing lentiviral transduction methods and verified them by flow cytometry analysis and RNA-seq. We found that the initial expansion of CD26 CAR-transduced T cells was delayed due to transient fratricide, but subsequent expansion was accelerated. CD26 CAR T cells exhibited cytotoxicity against the CD26+ T-cell lymphoma cell line Karpas 299, CD26-overexpressing K562 cells and primary CML LSCs, activated multiple effector functions in co-culture assays, and limited tumour progression in a mouse model; but there was some off-tumour cytotoxicity towards activated lymphocytes. In conclusion, these results establish the feasibility of using CD26 as an antigen for CAR T cells targeting CD26+ tumour cells.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhou S, Li W, Xiao Y, et al. A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells. Leukemia. 2020. PMID: 32317776. doi:10.1038/s41375-020-0824-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。